Latest Period
Q1 2026
Security Snapshot
REGENERON PHARMACEUTICALS, INC. - Common Stock (REGN) Institutional Ownership
CUSIP: 75886F107
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
1,390
Shares (Excl. Options)
88,727,798
Price
$772.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- REGN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 88,727,798
- Total 13F value
- $68,413,059,510
- Portfolio coverage rank
- 0.03%
- Share change
- -1,460,331
- Value change
- -$1,135,195,694
- Number of holders
- 1,390
- Shares outstanding
- 103,945,862
- SEC-reported price per share
- $623.54
- Insider filing price
- $623.54
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- REGN - REGENERON PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 75886F107.
- 1390 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1,390 to 553 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $68,413,059,510 to $3,292,406,303.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1390 institutions filings for Q1 2026.
Security key
75886F107
Latest holder period
Q1 2026
13F holders
1,390
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
REGN full holder history
REGENERON PHARMACEUTICALS, INC. SEC filings
REGENERON PHARMACEUTICALS, INC. company facts
REGENERON PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75886F107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
REGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4% | $5,919,048,238 | 7,660,810 | Vanguard Capital Management | 31 Mar 2026 | |||
| JPMORGAN CHASE & CO | 4.4% | -14% | $2,729,989,170 | -$462,704,633 | 4,742,611 | -14% | JPMORGAN CHASE & CO. | 30 May 2025 |
| FMR LLC | 3.2% | -55% | $1,880,548,739 | -$2,703,197,470 | 3,359,563 | -59% | FMR LLC | 30 Jun 2025 |
As of 31 Mar 2026, 1,390 institutional investors reported holding 88,727,798 shares of REGENERON PHARMACEUTICALS, INC. - Common Stock (REGN). This represents 85% of the company’s total 103,945,862 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
57%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.6% | 8,947,735 | +2.4% | 0.12% | $6,913,378,662 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.4% | 6,654,913 | 0% | 0.13% | $5,141,851,981 |
| STATE STREET CORP | 4.5% | 4,664,478 | +0.08% | 0.12% | $3,603,962,282 |
| Dodge & Cox | 4.3% | 4,458,238 | -3% | 1.9% | $3,444,613,008 |
| JPMORGAN CHASE & CO | 4.1% | 4,311,806 | +9.4% | 0.22% | $3,230,794,154 |
| FRANKLIN RESOURCES INC | 2.6% | 2,722,071 | +6.3% | 0.52% | $2,103,180,552 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 2,607,732 | +3.5% | 0.12% | $2,008,490,441 |
| Invesco Ltd. | 2.1% | 2,180,631 | -6% | 0.21% | $1,684,842,736 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 2,177,527 | +12% | 0.19% | $1,682,446,000 |
| Nuveen, LLC | 2% | 2,065,064 | +2.7% | 0.43% | $1,595,551,050 |
| LOOMIS SAYLES & CO L P | 1.8% | 1,912,310 | -1.1% | 2% | $1,477,527,279 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.8% | 1,837,459 | +177% | 0.27% | $1,419,694,322 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7% | 1,720,774 | 0% | 0.07% | $1,329,538,823 |
| FMR LLC | 1.5% | 1,518,192 | -35% | 0.06% | $1,173,016,067 |
| Capital World Investors | 1.4% | 1,419,000 | +1.5% | 0.15% | $1,096,375,503 |
| MORGAN STANLEY | 1.3% | 1,319,329 | -5% | 0.06% | $1,019,369,158 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,300,558 | +19% | 0.13% | $1,004,863,269 |
| AQR CAPITAL MANAGEMENT LLC | 1.2% | 1,231,008 | +24% | 0.43% | $946,005,238 |
| BANK OF AMERICA CORP /DE/ | 1.1% | 1,189,584 | +2.8% | 0.07% | $919,120,445 |
| Amundi | 0.97% | 1,009,798 | +28% | 0.21% | $780,210,326 |
| NORTHERN TRUST CORP | 0.91% | 941,941 | -0.32% | 0.1% | $727,781,294 |
| TWO SIGMA INVESTMENTS, LP | 0.78% | 812,236 | +189% | 0.52% | $627,566,023 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.77% | 804,508 | +3.4% | 0.09% | $621,595,061 |
| Bank of New York Mellon Corp | 0.74% | 765,411 | +0.15% | 0.11% | $591,387,063 |
| Legal & General Group Plc | 0.7% | 732,054 | -1.5% | 0.13% | $565,614,200 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 5,283,265 | $3,292,406,303 | -$81,735,737 | $623.54 | 553 |
| 2026 Q1 | 88,727,798 | $68,413,059,510 | -$1,135,195,694 | $772.64 | 1,390 |
| 2025 Q4 | 89,193,906 | $68,857,056,243 | +$1,928,512,727 | $771.87 | 1,379 |
| 2025 Q3 | 86,991,990 | $48,930,496,961 | -$1,213,231,743 | $562.27 | 1,235 |
| 2025 Q2 | 89,209,869 | $46,858,212,368 | -$1,426,702,234 | $525.00 | 1,192 |
| 2025 Q1 | 92,030,457 | $58,330,479,204 | -$1,189,685,324 | $634.23 | 1,275 |
| 2024 Q4 | 93,286,684 | $66,492,644,189 | -$479,615,848 | $712.33 | 1,299 |
| 2024 Q3 | 92,775,414 | $97,325,332,836 | -$1,389,777,813 | $1051.24 | 1,377 |
| 2024 Q2 | 94,041,724 | $98,807,158,234 | +$1,312,660,088 | $1051.03 | 1,326 |
| 2024 Q1 | 92,759,471 | $89,156,855,451 | +$2,508,878,899 | $962.49 | 1,301 |
| 2023 Q4 | 91,348,974 | $80,250,681,450 | +$167,710,733 | $878.29 | 1,264 |
| 2023 Q3 | 91,165,414 | $75,038,056,657 | -$525,679,317 | $822.96 | 1,169 |
| 2023 Q2 | 91,953,885 | $66,140,528,710 | -$553,052,249 | $718.54 | 1,156 |
| 2023 Q1 | 92,595,818 | $76,020,982,589 | +$89,011,870 | $821.67 | 1,182 |
| 2022 Q4 | 92,696,176 | $66,864,723,638 | -$266,120,511 | $721.49 | 1,147 |
| 2022 Q3 | 92,906,259 | $64,040,087,013 | -$168,708,759 | $688.87 | 1,066 |
| 2022 Q2 | 93,068,613 | $55,019,554,470 | +$640,020,015 | $591.13 | 1,053 |
| 2022 Q1 | 92,282,918 | $64,432,639,590 | +$1,537,895,341 | $698.42 | 1,082 |
| 2021 Q4 | 90,102,844 | $56,873,192,901 | +$52,711,404 | $631.52 | 1,065 |
| 2021 Q3 | 90,013,397 | $54,432,928,676 | +$779,583,867 | $605.18 | 1,008 |
| 2021 Q2 | 88,855,592 | $49,577,081,270 | -$361,559,165 | $558.54 | 959 |
| 2021 Q1 | 89,440,318 | $42,282,450,124 | -$390,555,615 | $473.14 | 906 |
| 2020 Q4 | 90,316,473 | $43,589,271,335 | -$890,178,034 | $483.11 | 892 |
| 2020 Q3 | 91,983,733 | $51,497,235,324 | -$511,019,782 | $559.78 | 899 |
| 2020 Q2 | 92,590,578 | $57,723,182,729 | +$10,927,851,201 | $623.65 | 923 |